This blog explores the formulation process of Staphylococcus albus tablets, focusing on how freeze-drying and dry granulation preserve live bacteria while ensuring tablet quality. It highlights key techniques that balance microbial viability with practical drug delivery for chemical wholesalers and pharmaceutical developers.

Freeze-Drying: The Foundation of Live Bacteria Preservation
The formulation process begins with raw material treatment, where Staphylococcus albus is cultured and centrifuged before vacuum freeze-drying at -40°C and 0.1Pa. This step, critical for chemical wholesalers supplying biological materials, controls moisture below 3% and achieves over 90% viable bacteria retention—40% higher than spray drying. The freeze-dried powder is then milled in a sterile environment to maintain flowability.

Excipient Selection: Protecting Viability Without Compromise
Excipient compatibility directly determines tablet stability. Microcrystalline cellulose at 30% serves as a filler offering flowability and disintegration properties, while 10% lactose acts as a lyoprotectant to preserve bacterial activity during rehydration. For chemical wholesalers focused on pharmaceutical-grade ingredients, avoiding bacteriostatic excipients like sodium benzoate is essential. All excipients undergo dry heat sterilization at 180°C for two hours.

Dry Granulation: Minimizing Live Bacteria Loss
Granulation method selection impacts final product quality. Dry granulation at 10-15MPa pressure avoids the moisture and heat of wet granulation, which can damage viable bacteria. Particles are controlled at 100-300μm, with tablet weight variation under 5%. The dry process limits viable bacteria loss to under 5%, compared to 20-30% for wet granulation—a decisive advantage for microbial formulations.

Tableting and Packaging: Ensuring Final Product Integrity
Tablet hardness is controlled at 3-5kgf to balance integrity with rapid disintegration (within 15 minutes). Packaging uses aluminum-plastic blister packs with desiccant (moisture adsorption ≥30%) and nitrogen flushing (oxygen content ≤1%), limiting viable bacteria decline to ≤10% annually. Storage at 2-8°C prevents heat-induced inactivation. These standards represent the precision chemical wholesalers must uphold.

Conclusion: A Blueprint for Microbial Drug Development
The formulation craft of Staphylococcus albus tablets reflects a delicate equilibrium between microbial viability and pharmaceutical performance. Through freeze-drying, dry granulation, and protective packaging, the process solves the core challenge of live bacteria loss during tableting. For chemical wholesalers and drug developers, this approach offers a viable pathway for microbial-based therapeutics.